Scholar Rock announced the appointment of Tracey Sacco as chief commercial officer. Sacco brings extensive biopharmaceutical industry experience, including product launch and global commercial strategy. At Scholar Rock, she will build and lead all commercial functions, including sales, marketing, market access, and commercial operations. Her first priority will be preparing the company for the potential commercial launch of apitegromab, the company’s Phase 3 investigational candidate for spinal muscular atrophy, or SMA. Most recently, Sacco worked at The Nemetz Group, where she served as a strategic partner to biopharmaceutical companies on commercialization and corporate strategy.
Published first on TheFly
